Traditionally, tumor size; status of nodal metastasis; and status of the estrogen receptor (ER), progesterone receptor (PR), and HER2 were taken as useful prognostic biomarkers for BRCA in the clinic [3–5]. Here, PGR is linked to neoplasm.